Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration

Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome

(2011) Heinrich Gerding et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme

(2010) Britta Heimes et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity

(2010) Philipp Sebastian Muether et al.   GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

(2009) Geeta A. Lalwani et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: The Second Year of a Prospective Study

(2009) Ziad F. Bashshur et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

(2008) Carl D. Regillo et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Relationship Between Optical Coherence Tomography Retinal Parameters and Visual Acuity in Neovascular Age-Related Macular Degeneration

(2008) Pearse A. Keane et al.   OPHTHALMOLOGY